These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 31159582)

  • 41. Heart failure: clinical problem and management issues.
    Nicklas JM; Bleske BE; Van Harrison R; Hogikyan RV; Kwok Y; Chavey WE
    Prim Care; 2013 Mar; 40(1):17-42. PubMed ID: 23402460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
    Ezekowitz JA; McMullan CJ; Westerhout CM; Piña IL; Lopez-Sendon J; Anstrom KJ; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Koglin J; Armstrong PW; Butler J;
    Circ Heart Fail; 2023 Sep; 16(9):e010599. PubMed ID: 37417824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
    Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
    ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database).
    Massoullié G; Chouki C; Mulliez A; Rossignol P; Ploux S; Pereira B; Reuillard A; Jean F; Andronache M; Eschalier A; Motreff P; Clerfond G; Bordachar P; Authier N; Eschalier R
    Am J Cardiol; 2018 Mar; 121(6):725-730. PubMed ID: 29402420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.
    DeVore AD; Al-Khatib SM
    JACC Heart Fail; 2019 Oct; 7(10):907-910. PubMed ID: 31521688
    [No Abstract]   [Full Text] [Related]  

  • 49. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
    Bangalore S; Kumar S; Messerli FH
    Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.
    Burnett H; Earley A; Voors AA; Senni M; McMurray JJ; Deschaseaux C; Cope S
    Circ Heart Fail; 2017 Jan; 10(1):e003529. PubMed ID: 28087688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current challenges in the management of heart failure.
    Komajda M
    Circ J; 2015; 79(5):948-53. PubMed ID: 25877621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry.
    Zusterzeel R; Spatz ES; Curtis JP; Sanders WE; Selzman KA; Piña IL; Bao H; Ponirakis A; Varosy PD; Masoudi FA; Caños DA; Strauss DG
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S4-11. PubMed ID: 25714821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of heart failure in patients with reduced left- ventricular ejection fraction].
    Elskjær H
    Ugeskr Laeger; 2018 Oct; 180(20A):. PubMed ID: 30274585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial.
    Merkely B; Kosztin A; Roka A; Geller L; Zima E; Kovacs A; Boros AM; Klein H; Wranicz JK; Hindricks G; Clemens M; Duray GZ; Moss AJ; Goldenberg I; Kutyifa V
    Europace; 2017 Sep; 19(9):1549-1555. PubMed ID: 28339581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older.
    Adelstein EC; Liu J; Jain S; Schwartzman D; Althouse AD; Wang NC; Gorcsan J; Saba S
    Europace; 2016 Mar; 18(3):420-7. PubMed ID: 26487669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    DeFilippis EM; Butler J; Vaduganathan M
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29138249
    [No Abstract]   [Full Text] [Related]  

  • 58. Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48).
    Chan D; Doughty RN; Mazengarb J; McLachlan A; Kerr AJ
    N Z Med J; 2020 Jun; 133(1516):58-71. PubMed ID: 32525862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
    Naegele M; Flammer AJ; Enseleit F; Ruschitzka F
    Swiss Med Wkly; 2016; 146():w14295. PubMed ID: 26968014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
    Samsky MD; Lin L; Greene SJ; Lippmann SJ; Peterson PN; Heidenreich PA; Laskey WK; Yancy CW; Greiner MA; Hardy NC; Kavati A; Park S; Mentz RJ; Fonarow GC; O'Brien EC
    JAMA Cardiol; 2020 Mar; 5(3):292-299. PubMed ID: 31734700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.